Chronic VEGF blockade worsens glomerular injury in the remnant kidney model

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Machado, Flavia G ^a   KurikiPatrí, Patrícia Semedo ^b   Fujihara, Clarice K ^a   Fanelli, Camilla ^a   Arias, Simone C A ^a   Malheiros, Denise M A C ^a   Camara, Niels O S ^b   Zatz, Roberto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB; VASCULOTROPIN;

ADULT ANIMAL; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY; CONTROLLED STUDY; DISEASE EXACERBATION; GENE EXPRESSION; GLOMERULOSCLEROSIS; GLOMERULUS INJURY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY INJURY; KIDNEY INTERSTITIUM; MALE; MORPHOLOGY; NONHUMAN; PODOCYTE; PROTEINURIA;

ANIMALS; CATHETER ABLATION; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; INDOLES; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; PYRROLES; RATS; RATS, WISTAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862685208     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039580     Document Type: Article

References (53)

1. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, et al. (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309-1312.
2. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N, (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309.
3. Plouet J, Schilling J, Gospodarowicz D, (1989) Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 8: 3801-3806.
4. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, et al. (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985.
5. Schrijvers BF, Flyvbjerg A, De Vriese AS, (2004) The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65: 2003-2017.
6. Guan F, Villegas G, Teichman J, Mundel P, Tufro A, (2006) Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am J Physiol Renal Physiol 291: F422-428.
7. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G, (2007) Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 50: 203-218.
8. Izzedine H, Buhaescu I, Rixe O, Deray G, (2007) Sunitinib malate. Cancer Chemother Pharmacol 60: 357-364.
9. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, et al. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327-337.
10. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, et al. (2010) VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 46: 439-448.
11. Eckardt KU, Bernhardt WM, Weidemann A, Warnecke C, Rosenberger C, et al. (2005) Role of hypoxia in the pathogenesis of renal disease. Kidney Int.
12. Tanaka T, Nangaku M, (2010) The role of hypoxia, increased oxygen consumption, and hypoxia-inducible factor-1 alpha in progression of chronic kidney disease. Curr Opin Nephrol Hypertens 19: 43-50.
13. Mimura I, Nangaku M, (2010) The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol 6: 667-678.
14. Rodriguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chavez M, et al. (2002) Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 282: F191-201.
15. Eremina V, Baelde HJ, Quaggin SE, (2007) Role of the VEGF-a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 106: p32-37.
16. Kappers MH, van Esch JH, Sleijfer S, Danser AH, van den Meiracker AH, (2009) Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. J Hypertens 27: 2297-2309.
17. Gerber HP, Dixit V, Ferrara N, (1998) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273: 13313-13316.
18. Spyridopoulos I, Brogi E, Kearney M, Sullivan AB, Cetrulo C, et al. (1997) Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: balance between growth and death signals. J Mol Cell Cardiol 29: 1321-1330.
19. Ahmed A, Singh J, Khan Y, Seshan SV, Girardi G, (2010) A new mouse model to explore therapies for preeclampsia. PLoS One 5: e13663.
20. Brown LF, Berse B, Tognazzi K, Manseau EJ, Van de Water L, et al. (1992) Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 42: 1457-1461.
21. El Awad B, Kreft B, Wolber EM, Hellwig-Burgel T, Metzen E, et al. (2000) Hypoxia and interleukin-1beta stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int 58: 43-50.
22. Sison K, Eremina V, Baelde H, Min W, Hirashima M, et al. (2010) Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 21: 1691-1701.
23. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, et al. (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 1129-1136.
24. Eremina V, Quaggin SE, (2010) Biology of anti-angiogenic therapy-induced thrombotic microangiopathy. Semin Nephrol 30: 582-590.
25. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, et al. (2010) Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 56: 675-681.
26. Gkountouvas A, Kostoglou-Athanassiou I, Veniou E, Repousis P, Ziras N, et al. (2010) Hematologic toxicity in patients treated with sunitinib for advanced thyroid cancer. Thyroid 20: 597-600.
27. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
28. Kubo H, Alitalo K, (2003) The bloody fate of endothelial stem cells. Genes Dev 17: 322-329.
29. Schatteman GC, Awad O, (2004) Hemangioblasts, angioblasts, and adult endothelial cell progenitors. Anat Rec A Discov Mol Cell Evol Biol 276: 13-21.
30. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, et al. (2001) Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 12: 1434-1447.
31. Wu Q, Du Y, Yang N, Liang Y, Li Y, (2006) Microvasculature change and placenta growth factor expression in the early stage of a rat remnant kidney model. Am J Nephrol 26: 97-104.
32. Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, et al. (1992) Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 41: 297-309.
33. Fujihara CK, Malheiros DM, Zatz R, Noronha IL, (1998) Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 54: 1510-1519.
34. Yang N, Wu LL, Nikolic-Paterson DJ, Ng YY, Yang WC, et al. (1998) Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney. Nephrol Dial Transplant 13: 1967-1974.
35. Kelly DJ, Hepper C, Wu LL, Cox AJ, Gilbert RE, (2003) Vascular endothelial growth factor expression and glomerular endothelial cell loss in the remnant kidney model. Nephrol Dial Transplant 18: 1286-1292.
36. Eardley KS, Kubal C, Zehnder D, Quinkler M, Lepenies J, et al. (2008) The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int 74: 495-504.
37. Manotham K, Tanaka T, Matsumoto M, Ohse T, Miyata T, et al. (2004) Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 15: 1277-1288.
38. Anderson S, Meyer TW, Rennke HG, Brenner BM, (1985) Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76: 612-619.
39. Fujihara CK, Malheiros DM, Zatz R, (2007) Losartan-hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model. Am J Physiol Renal Physiol 292: F1810-1818.
40. Schrijvers BF, Flyvbjerg A, Tilton RG, Rasch R, Lameire NH, et al. (2005) Pathophysiological role of vascular endothelial growth factor in the remnant kidney. Nephron Exp Nephrol 101: e9-15.
41. Flyvbjerg A, Schrijvers BF, De Vriese AS, Tilton RG, Rasch R, (2002) Compensatory glomerular growth after unilateral nephrectomy is VEGF dependent. Am J Physiol Endocrinol Metab 283: E362-366.
42. Lax DS, Benstein JA, Tolbert E, Dworkin LD, (1992) Effects of salt restriction on renal growth and glomerular injury in rats with remnant kidneys. Kidney Int 41: 1527-1534.
43. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, et al. (1993) Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest 92: 2597-2601.
44. Nagata M, Kriz W, (1992) Glomerular damage after uninephrectomy in young rats. II. Mechanical stress on podocytes as a pathway to sclerosis. Kidney Int 42: 148-160.
45. Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, et al. (2005) Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 16: 1733-1741.
46. Kretzler M, Schroppel B, Merkle M, Huber S, Mundel P, et al. (1998) Detection of multiple vascular endothelial growth factor splice isoforms in single glomerular podocytes. Kidney Int pp. S159-161.
47. Foster RR, Hole R, Anderson K, Satchell SC, Coward RJ, et al. (2003) Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol 284: F1263-1273.
48. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L, (2006) VEGF receptor signalling- in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
49. Bollee G, Patey N, Cazajous G, Robert C, Goujon JM, et al. (2009) Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 24: 682-685.
50. Costero O, Picazo ML, Zamora P, Romero S, Martinez-Ara J, et al. (2010) Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol Dial Transplant 25: 1001-1003.
51. Jepsen FL, Mortensen PB, (1979) Interstitial fibrosis of the renal cortex in minimal change lesion and its correlation with renal function. A quantitative study. Virchows Arch A Pathol Anat Histol 383: 265-270.
52. Hirose K, Osterby R, Nozawa M, Gundersen HJ, (1982) Development of glomerular lesions in experimental long-term diabetes in the rat. Kidney Int 21: 689-695.
53. Wallenstein S, Zucker CL, Fleiss JL, (1980) Some statistical methods useful in circulation research. Circ Res 47: 1-9.